Abstract:Whooping cough (pertussis) is a highly contagious vaccine preventable respiratory disease caused by the Gram-negative bacterium Bordetella pertussis . Despite high level vaccination coverage over the past 20 years, Australia has one of the highest per capita burdens of pertussis globally. One of the primary factors associated with the re-emergence of pertussis is pathogen adaptation of B. pertussis to the current acellular vaccines used. This article will focus on the genomic and proteomic changes that have occurred in the Australian B. pertussis population, the significance of these adaptive changes on fitness in a vaccinated environment and what we can do to reduce the significant burden of pertussis in the future. Pertussis vaccinations were first introduced in Australia in 1953 using a whole cell vaccine (WCV), which contained dead B. pertussis cells. This led to a dramatic reduction in the number of pertussis notifications from 767 cases per 100 000 in the 1930s to one case per 100 000 by the late 1970s 1 . Despite the success of WCVs in reducing pertussis, reports of possible severe side-effects reduced public confidence in the vaccine and led to the replacement of the WCV with a new acellular vaccine (ACV) 2 . ACV was introduced into Australia in 1997, initially as a booster, and by 2000 it was used for all immunisations 2 . There are two ACVs used in Australia, the three component-ACV and the less widely used five-component ACV. The three-component ACV targets three virulence factors; pertussis toxin (Ptx), pertactin (Prn) and filamentous haemagglutinin (Fha), while the five-component vaccine targets two additional fimbriae (Fim2 and Fim3). Since the late 1990s, there has been a steady increase in pertussis notifications observed in Australia and in 2008–2012, Australia experienced a prolonged pertussis epidemic ( Figure 1 ). At the height of the epidemic in 2011, 174 cases per 100 000 were recorded, the highest number documented since the introduction of pertussis vaccination 2 . This was followed by a smaller yet still significant epidemic from 2014-2017 with a peak of 95 cases per 100 000 in 2015 3 ( Figure 1 ). Similar trends in increased notification rates have been noted in other countries that switched to the ACV 4 – 6 . To determine how B. pertussis is adapting to vaccine selection pressure, molecular epidemiology typing studies were performed to define the population structure and trace the evolution of B. pertussis in Australia from the pre-vaccination and WCV era to the ACV era. A previous single nucleotide polymorphism (SNP) typing study separated the global pertussis population into 6 SNP clusters (I-VI) based on 65 SNPs 7 . Australian B. pertussis isolates were mostly found in SNP clusters I-IV with SNP cluster V being a minor Australian cluster and SNP cluster VI containing vaccine and pre-vaccine strains. In the WCV period, SNP cluster II was the predominant cluster and was comprised of 33% of strains typed. After the switch to the ACV, the frequency of SNP cluster II isolates decreased to 11% and was replaced with SNP cluster I, which increased to 31% after it emerged during the WCV/ACV transition period 7 ( Figure 2 ). Since the 2008–2012 epidemic, the majority (>90%) of circulating strains in Australia belong to SNP cluster I 3 , 8 . Most current circulating strains in other ACV countries typed as ptxP3 strains are equivalent to SNP cluster I 9 . The replacement of the WCV with ACV in Australia reduced the number of antigens targeted from hundreds to 3-5 ( Figure 2 ). This has placed greater selection pressure on genes encoding ACV antigens to change and allow for vaccine escape variants to emerge in Australia. There are two major evolutionary changes observed due to increased vaccine selection pressure: ACV allelic divergence and inactivation of ACV antigen expression ( Figure 2 ). The greatest ACV allelic divergence is seen in ptxA and prn alleles. SNP cluster I carries the prn2 and ptxA1 alleles which encode antigenic variants that differ from the prn1 and ptxA2 alleles in Tohama I, the strain used to produce the W -Abstract Truncated-

Th1 polarization in Bordetella pertussis vaccine responses is maintained through a positive feedback loop

Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis

Genome-based prediction of cross-protective, HLA-DR-presented epitopes as putative vaccine antigens for multiple Bordetella species

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis, Including Pertactin Deficient Strains

Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions

Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates

IL-17 and IFN-γ-producing respiratory tissue resident memory CD4 T cells persist for decades in adults immunized as children with whole cell pertussis vaccines

Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells

Programming Bordetella pertussis lipid A to promote adjuvanticity

A novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigens

The mature c-terminal domain of filamentous hemagglutinin is sufficient to provide protection against Bordetella pertussisin the murine nasal cavity

Better recognition of whooping cough in older people

Bystander activation of Bordetella pertussis‐induced nasal tissue‐resident memory CD4 T cells confers heterologous immunity to Klebsiella pneumoniae

BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models

Generating enhanced mucosal immunity against Bordetella pertussis: current challenges and new directions

Outer membrane vesicles derived from Bordetella pertussis are potent adjuvant that drive Th1-biased response

Antibody Profiles Elicited by Potent and Subpotent Whole Cell Pertussis Vaccines in Mice

Reduced Bordetella pertussis-specific CD4+ T-Cell Responses at Older Age

Development and biological properties of an attenuated Bordetella pertussis strain

Pathogen adaptation to vaccination: the Australian Bordetella pertussis story